Metabolism Research

Metabolism, the biochemical network sustaining life, encompasses all the chemical reactions within the body. Breakthroughs in understanding metabolic dysregulation have led to significant advancements in treating diseases like diabetes, cardiovascular issues, obesity, and inherited metabolic disorders. At the molecular level, many metabolic diseases share converging pathological mechanisms. For instance, insulin resistance, the hallmark of type 2 diabetes, also contributes to impaired glucose metabolism in neurodegenerative conditions like Alzheimer’s disease. Lipotoxicity, another good example of being not just an isolated phenomenon, contributes to the development of various metabolic disorders, including type 2 diabetes, heart disease, and liver disease through disrupting normal cellular functions and causing damage.

Recent advances in cellular model systems have revolutionized our capacity to dissect these complex mechanisms and translate fundamental insights into therapeutic strategies. Induced pluripotent stem cells (iPSCs) derived from patients offer unique insights into tissue-specific pathologies. These cells can be precisely differentiated into functionally relevant cell types for disease modeling, such as glucose-insensitive β-cells modeling monogenic diabetes, arrhythmogenic cardiomyocytes simulating hypertrophic cardiomyopathy, or lipid-laden hepatocytes replicating the pathological lipid accumulation characteristic of non-alcoholic fatty liver disease (NAFLD).

Complementing these cellular models, CRISPR-Cas9 gene editing technology facilitates the precise dissection of disease-relevant genes functions. In diabetes research, CRISPR-engineered β-cells exhibiting immune-evasive properties demonstrate efficacy in restoring glycemic control in preclinical models. In cardiovascular disease investigations, base editing of the PCSK9 gene in hepatocytes successfully mimics naturally occurring loss-of-function mutations, significantly lowering LDL cholesterol levels to prevent atherosclerotic cardiovascular disease. Moreover, these advanced cell-based platforms are accelerating drug repurposing initiatives. For example, studies utilizing these models have expanded the potential therapeutic role of metformin beyond type 2 diabetes management to include rare disorders, such as mitochondrial myopathies. Similarly, glucagon-like peptide-1 (GLP-1) receptor agonists, traditionally used for glycemic control, have demonstrated significant anti-inflammatory effects within cardiovascular disease contexts. Crucially, scientific validity and translational potential of these innovations depend fundamentally on reliable, physiologically relevant cellular models that accurately recapitulate human pathophysiology. These models serve as essential tools bridging the gap between basic research and translational medicine.

AcceGen provides rigorously validated, high-quality cell product solutions specifically tailored for diverse metabolic disease research applications, facilitating investigations into metabolic signaling pathway dysregulation, therapeutic candidate screening, and precision medicine development.